A 2-year longitudinal PBMC gene expression profiling of MS patients receiving interferon-beta 1b predicts therapy outcome

Objective: A systematic time-dependent gene expression analysis from Interferon beta 1b (IFNbeta-1b) treated Multiple sclerosis (MS) patients delivers sets of genes that provide a rational basis for predicting the success in modulation of the disease course. Background: Microarrays are facilitating medical research by documenting detailed responses of cells and tissues to both disease and the intended and unintended effects of drug treatments. Method: Two independent cohorts of RRMS patients were classified by stringent clinical criteria as IFNbeta-1b responders or non-responders after 2 years follow-up. Using A…